Work Advice: How to help a friend stuck on the career ladder
Reader: I'm writing on behalf of a dear friend who is the 'rugged individualist' type and not one to seek outside help or advice. She has climbed the corporate ladder to a director-level position and is well regarded in her field. She enjoys working on data analysis and research but is weary of administrative and managerial chores like vendor contracts and annual reviews. Also, she has hit a wall: There's no real opportunity to move further up at her firm, and there are very few firms in her industry with a department focused on her skill set. She has been in contact with recruiters, but nothing has come up. She's a few years from retirement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Scott Galloway Reached His Financial Goal 8 Years Ago. He Says There's Just No Justification For Becoming A Billionaire
Scott Galloway had a plan: sell his company, take $25 million, raise another $250 million, and become a billionaire. But then he stopped to think about it. 'Why would I want back on this hamster wheel of stress?' he asked on a recent episode of his podcast, 'Office Hours.' Galloway, a business professor, entrepreneur and investor, said he realized the pursuit of more wealth would just cost him time, peace of mind and family moments. 'I've been doing nothing but working for a quarter century,' he said. After hitting his personal financial target, he made a different choice: spend on what brings joy, pay people well, and give the rest away. 'I hit my number eight years ago,' he said. 'And I decided there's just no reason why I would ever need to be a billionaire.' Don't Miss: Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can invest with $1,000 at just $0.30/share. Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. 'Every year I look at my number,' he explained. 'Anything above that number, I do one of two things: I either spend it or I give it away.' He added, 'It feels amazing to spend money and to give it away.' He owns a plane and refuses to let money prevent him from enjoying life. When friends can't afford to join, he covers the cost himself, saying it gives him satisfaction. His shift in mindset mirrors that of Andrew Wilkinson, a Canadian entrepreneur who told his own story in the 2024 book, 'Never Enough.' Wilkinson became a billionaire after building the tech conglomerate Tiny, but eventually saw the limits of wealth. After nearly partnering with legendary investor Charlie Munger, Wilkinson said he turned it down. The thought of chasing another level of wealth no longer appealed to him. Both Wilkinson and Galloway reached a similar conclusion. Once you have enough, more doesn't necessarily improve your life. In fact, it can increase stress. Trending: GoSun's Breakthrough Rooftop EV Charger Already Has 2,000+ Units Reserved — Become an Investor in This $41.3M Clean Energy Brand Today Galloway recalls the fear he felt in 2008 when his first son was born during the financial crisis. 'All I felt was shame and fear,' he said. 'I thought, I've failed this kid. I don't have enough money.' That fear stayed with him until he reached financial security. 'Happiness is not only a function of the things you have,' he said. 'It's a function of the things that you don't have—specifically, an absence from stress.' Galloway also wants to normalize open conversations about money. 'This zeitgeist that you're not supposed to talk about money is nothing but an effort by rich people to keep the poor and middle class down,' he said. He encourages people to share information about salaries, taxes and financial tools to help each other get ahead. 'Talking about it a lot gives you ideas and opportunities and can be quite cathartic,' he said. These days, Galloway says he's off the hamster wheel for good. He spends on joy, gives generously and says he finally feels free. Read Next: Maximize saving for your retirement and cut down on taxes: Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. Are you rich? Here's what Americans think you need to be considered 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article Scott Galloway Reached His Financial Goal 8 Years Ago. He Says There's Just No Justification For Becoming A Billionaire originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Jeff Andrews: 'Never seen culture better than it is right now' at Hendrick Motorsports
Jeff Andrews: 'Never seen culture better than it is right now' at Hendrick Motorsports Jeff Andrews, president of Hendrick Motorsports, gives his insight into the current culture of Hendrick Motorsports after Chase Elliott's victory.
Yahoo
an hour ago
- Yahoo
Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week
The company's CFO resigned from his position. One law firm wasn't shy about reminding investors of the departure. 10 stocks we like better than Iovance Biotherapeutics › There's nothing like a top-level management departure to get investors worried about a publicly traded company. Investors in biotech stock Iovance Therapeutics (NASDAQ: IOVA) were served a strong reminder of the company's latest executive departure earlier in the week. With that headwind blowing in its face, Iovance's shares lost almost 15% of their value during the week, according to data compiled by S&P Global Market Intelligence. Hagens Berman Sobol Shapiro, one of the numerous law firms currently investigating Iovance's activities, was behind the reminder. It pointed out that CFO Jean-Marc Bellemin stepped down from his post earlier in June. His resignation is effective this coming July 10. The law firm hinted that the cancer-focused biotech company's legal headaches were at least partially responsible for this. It wrote in a press release that "Bellemin's exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the specter of a class action securities lawsuit." Iovance originally disclosed the CFO's resignation on Friday, June 13 in a tersely worded regulatory filing with the Securities and Exchange Commission (SEC). It said only that Bellemin made the move "to pursue other opportunities." It did not elaborate on this. Besides its legal headaches, Iovance is struggling to produce impressive fundamentals. Although it delivered decent top-line growth -- thanks to Amtagvi, a melanoma drug -- it made quite a drastic cut to its product-revenue guidance for the entirety of this year. I don't think Iovance is in a good place just now. However, Amtagvi still has much potential, and the biotech is a player to watch in the cancer space. It might just be worthy of a buy for investors with a large appetite for risk. Before you buy stock in Iovance Biotherapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Iovance Biotherapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $704,676!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $950,198!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy. Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week was originally published by The Motley Fool Sign in to access your portfolio
